Shape

Apogee Therapeutics is a clinical stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology markets, including for the treatment of atopic dermatitis asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis and other I&I indications.

Photo of smiling baby with atopic dermatitis rash around mouth

Our philosophy is simple.

Our goal is to discover and develop novel therapies for a range of I&I indications. We aim to accomplish this goal by focusing on known biologic drivers of disease and utilizing advanced antibody engineering to develop product candidates with optimized properties that have the potential to overcome limitations of existing therapies. We believe our approach will enable us to develop a portfolio of therapies that are differentiated compared to the currently available standards of care and address unmet medical needs for I&I indications.

Improving treatment options for people with inflammatory and immune diseases

At Apogee, we are advancing both monotherapies and rational combinations of therapeutic antibody product candidates. Our ongoing and planned clinical studies aim to study the safety and efficacy of our next generation product candidates to target I&I diseases.

Our antibody programs are designed to overcome limitations of existing therapies by leveraging well-established mechanisms and incorporating advanced antibody engineering to optimize half-life and other properties. Our ongoing study is testing APG777 dosed either every three or six months in maintenance, which, if our clinical trials are successful, would represent a significant improvement compared to currently available antibodies that are dosed every two to four weeks. We believe each of our programs has potential for broad application across multiple I&I indications.

Pipeline

STRATEGY
PROGRAM
Discovery
PRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
NEXT ANTICIPATED MILESTONES

Potential best-in-class monotherapy in AD

Higher exposures for better efficacy with less frequent dosing

APG777

IL-13

ATOPIC DERMATITIS

ATOPIC DERMATITIS

PHASE 2

  • Mid-2025: Phase 2 16-week induction PoC data

  • 1H 2026: Phase 2 Part A 52-week data

  • 2H 2026: Phase 2 Part B 16-week data

ASTHMA

ASTHMA

PHASE 1

  • 1H 2025: Phase 1b trial initiation

  • 2H 2025: Phase 2b trial initiation

  • 2026: Phase 1b data

EOE

EOE

PHASE 1

  • 2026: Clinical trial initiation

Potential first- or best-in-class combination approaches

APG777 + APG990

IL-13 + OX40L

ATOPIC DERMATITIS

ATOPIC DERMATITIS

PRE-CLINICAL

  • 2025: Phase 1b PoC trial initiation (vs.DUPIXENT)

  • 2H 2026: Phase 1b PoC data (against DUPIXENT)

APG777 + APG333

IL-13 + TSLP

ASTHMA

ASTHMA

PRE-CLINICAL

  • 2025: Additional clinical plan announced

COPD

COPD

PRE-CLINICAL

  • 2025: Additional clinical plan announced

  • APG808 (IL-4Rα)

    Ph1b in mild asthma readout expected in 1H 2025

  • APG990 (OX40L)

    Phase 1 healthy volunteer readout expected in 1H 2025

  • APG333 (TSLP)

    Phase 1 healthy volunteer readout expected in 2H 2025